Suppr超能文献

多区域实施倡议对心力衰竭住院患者基于指南的绩效指标的影响:IMPLEMENT-HF研究

Multiregional Implementation Initiative's Impact on Guideline-Based Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF.

作者信息

Sauer Andrew J, Beon Chandler, Cherkur Sruthi, Mallas-Serdynski Lynn, Thomas Kathie, Spertus John, Chahoud Georges, Mody Kanika P, Saltzberg Mitchell T, Goldberg Lee R, Lindenfeld JoAnn, Sweitzer Nancy, Butler Javed, Kittleson Michelle M, Pina Ileana, Paul Sara, Lewis Eldrin F, Wald Joyce, Allen Larry A, Jessup Mariell, Congdon Michelle, Kiser Robin, Yancy Clyde, Fonarow Gregg C

机构信息

Saint Luke's Mid-America Heart Institute, Kansas City, MO (A.J.S., J.S.).

American Heart Association, Dallas, TX (C.B., S.C., L.M.-S., K.T., M.J., M.C., R.K.).

出版信息

Circ Heart Fail. 2025 May;18(5):e012547. doi: 10.1161/CIRCHEARTFAILURE.124.012547. Epub 2025 Mar 21.

Abstract

BACKGROUND

Despite randomized data for survival benefit (with class 1 recommendations) for treating heart failure (HF) with reduced ejection fraction using quadruple medical therapy (QMT)-defined as evidence-based β-blockers, sodium-glucose cotransporter 2 inhibitor, preferably angiotensin receptor/neprilysin inhibitor, and mineralocorticoid receptor antagonist-it is underutilized. IMPLEMENT-HF is a multiregional HF quality improvement initiative to improve care and outcomes for patients with HF by enhancing the use of QMT in routine practice.

METHODS

This analysis of HF with reduced ejection fraction treatment in patients from hospitals participating in the American Heart Association's Get With The Guidelines-HF who volunteered to participate in IMPLEMENT-HF in 7 US regions. IMPLEMENT-HF included multidisciplinary learning to share strategies for formulary changes, electronic health record tools, and patient resources with site-level feedback reports. Participants gathered QMT data at discharge and 30 days after discharge. We evaluated QMT utilization and variation, in addition to other prespecified performance measures, from Q1 2021 to Q2 2023.

RESULTS

The median (interquartile range) age of 43 558 admitted patients at 61 hospitals was 74 (63-83) years; 16 530 (38%) belonged to racial and ethnic minorities, and 22 228 (51%) were women. Between Q1 2021 and Q2 2023, defect-free QMT improved from 4.7% to 44.6% at discharge and from 0% to 44.8% at 30 days (both <0.0001). There was also substantially improved incorporation of health-related social needs assessments. The magnitude of improvements was similar when stratified by sex or race and ethnicity, yet there was significant regional variation.

CONCLUSIONS

Among healthcare systems participating in IMPLEMENT-HF, there was a marked increase in QMT use among eligible patients over the course of the initiative. This quality improvement initiative supports a learning collaborative model to promote improvements in QMT use.

摘要

背景

尽管有随机数据表明,使用四重药物治疗(QMT)——定义为循证β受体阻滞剂、钠-葡萄糖协同转运蛋白2抑制剂(最好是血管紧张素受体/脑啡肽酶抑制剂)和盐皮质激素受体拮抗剂——治疗射血分数降低的心力衰竭(HF)可带来生存获益(有I类推荐),但该治疗方法未得到充分利用。IMPLEMENT-HF是一项多地区HF质量改进计划,旨在通过在常规实践中加强QMT的使用来改善HF患者的护理和预后。

方法

对参与美国心脏协会“遵循指南-心力衰竭”项目且自愿参与美国7个地区IMPLEMENT-HF的医院中射血分数降低的HF患者进行治疗分析。IMPLEMENT-HF包括多学科学习,以分享处方集变更策略、电子健康记录工具和患者资源,并提供现场级反馈报告。参与者在出院时和出院后30天收集QMT数据。我们评估了2021年第一季度至2023年第二季度期间QMT的使用情况和差异,以及其他预先指定的绩效指标。

结果

61家医院的43558名入院患者的中位(四分位间距)年龄为74(63-83)岁;16530名(38%)属于少数种族和族裔,22228名(51%)为女性。在2021年第一季度至2023年第二季度期间,出院时无缺陷QMT从4.7%提高到44.6%,30天时从0%提高到44.8%(均<0.0001)。与健康相关的社会需求评估的纳入情况也有显著改善。按性别或种族和族裔分层时,改善幅度相似,但存在显著的地区差异。

结论

在参与IMPLEMENT-HF的医疗系统中,在该计划实施过程中,符合条件的患者对QMT的使用显著增加。这一质量改进计划支持一种学习协作模式,以促进QMT使用的改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbb7/12084012/2428775d1af8/hhf-18-e012547-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验